Inclusion Criteria:  Undergoing treatment with brentuximab vedotin (of less than 3 months from initial treatment with brentuximab vedotin) or to be received with brentuximab vedotin. CD30-positive lymphoma by INV (any CD30 expression)  Exclusion Criteria:  1. Who currently participates in or with plan to participate in any interventional clinical trial.